Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5-ethynyluracil
2. 776c85
3. Compound 776c
4. Gw776c85
1. 59989-18-3
2. 5-ethynyluracil
3. 5-ethynylpyrimidine-2,4(1h,3h)-dione
4. 5-ethynyl-1h-pyrimidine-2,4-dione
5. Gw776c85
6. 776c85
7. 5-ethynyl-2,4(1h,3h)-pyrimidinedione
8. 5-ethynyl-2-hydroxypyrimidin-4(1h)-one
9. 5-ethynyl-6-hydroxypyrimidin-2(1h)-one
10. 5-ethynyl-2,4(1h,3h)pyrimidinedione
11. 2e2w0w5xiu
12. Chembl355200
13. Compound 776c
14. 5-ethynylpyrimidine-2,4(1h,3h)-dione.
15. 776-c-85
16. Eniluracil [usan]
17. 5-ethynylpyrimidine-2,4-diol
18. Unii-2e2w0w5xiu
19. 5-ethynyl-2-hydroxypyrimidin-4(3h)-one
20. 5-ethynyl-4-hydroxypyrimidin-2(1h)-one
21. Eniluracil [usan:inn:ban]
22. 2,4(1h,3h)-pyrimidinedione, 5-ethynyl-
23. 5-ethynyl-uracil
24. Y3g
25. Eniluracil [mi]
26. Eniluracil [inn]
27. Eniluracil (usan/inn)
28. Eniluracil [mart.]
29. Eniluracil [who-dd]
30. Schembl37817
31. Zinc5467
32. Dtxsid10208696
33. Chebi:177783
34. Hms3745i03
35. Bdbm50124202
36. Geo-02731
37. Gw-776
38. Mfcd00871973
39. Nsc687296
40. Zb1821
41. Akos006240058
42. Akos016009479
43. Adh-300004
44. Db03516
45. Nsc-687296
46. As-66226
47. Hy-10533
48. Cs-0002630
49. E1096
50. Ft-0667865
51. D03998
52. T72682
53. A857850
54. Q27094456
| Molecular Weight | 136.11 g/mol |
|---|---|
| Molecular Formula | C6H4N2O2 |
| XLogP3 | -0.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 1 |
| Exact Mass | 136.027277375 g/mol |
| Monoisotopic Mass | 136.027277375 g/mol |
| Topological Polar Surface Area | 58.2 Ų |
| Heavy Atom Count | 10 |
| Formal Charge | 0 |
| Complexity | 269 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of cancer in combination with 5-fluorouracil.
Eniluracil is an orally active dihydropyrimidine dehydrogenase (DPD) inhibitor, designed to enhance activity of chemotaxic agents. It is under investigation by Adherex, under license from GlaxoSmithKline, for the treatment of cancer in combination with 5-fluorouracil (5-FU).
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Normally, 5-FU is rapidly broken down in the body by an enzyme known as dihydropyrimidine dehydrogenase (DPD). Eniluracil irreversibly inhibits DPD, thereby substantially slowing the breakdown of 5-FU and prolonging exposure of the tumor cells to the drug.
ABOUT THIS PAGE
A Eniluracil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Eniluracil, including repackagers and relabelers. The FDA regulates Eniluracil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Eniluracil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Eniluracil supplier is an individual or a company that provides Eniluracil active pharmaceutical ingredient (API) or Eniluracil finished formulations upon request. The Eniluracil suppliers may include Eniluracil API manufacturers, exporters, distributors and traders.
Eniluracil Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Eniluracil GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Eniluracil GMP manufacturer or Eniluracil GMP API supplier for your needs.
A Eniluracil CoA (Certificate of Analysis) is a formal document that attests to Eniluracil's compliance with Eniluracil specifications and serves as a tool for batch-level quality control.
Eniluracil CoA mostly includes findings from lab analyses of a specific batch. For each Eniluracil CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Eniluracil may be tested according to a variety of international standards, such as European Pharmacopoeia (Eniluracil EP), Eniluracil JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Eniluracil USP).
LOOKING FOR A SUPPLIER?
